
Opinion|Videos|February 10, 2025
Clinical Trial Evidence in Second-Line Treatment: Analysis of Response Criteria and Patient Selection
Author(s)Aaron T. Gerds, MD, MS, Jeanne Palmer, MD
Panelists discuss how clinical trial data inform the selection of second-line therapies for patients with myelofibrosis, focusing on response assessment criteria and identifying optimal candidates for various treatment options.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















